Further evidence of a chemotherapy predictive potential for uPA/PAI-1 was obtained by using data from two separate sites (n = 3,424), which showed that breast cancer patients with high levels of the biomarkers derived an enhanced benefit from adjuvant chemotherapy (mostly CMF) than those with low levels [79]. Here, PLAU is linked to breast cancer.